LAS VEGAS, Aug. 13, 2026 /PRNewswire/ -- Recently published Bronchiectasis Market Insights report includes a comprehensive understanding of current treatment practices, bronchiectasis emerging drugs, ...
For the first time, people with bronchiectasis will have a treatment option. The U.S. Food and Drug Administration has approved Insmed's daily pill brensocatib, which will be sold under the brand name ...
The American College of Chest Physicians (CHEST) has released a new clinical guideline on the management of adult bronchiectasis. Published in the journal CHEST, the guideline contains 13 ...
For the first time, people with bronchiectasis will have a treatment option. The U.S. Food and Drug Administration (FDA) has approved Insmed's daily pill brensocatib, which will be sold under the ...
Synchrony Medical, a respiratory care technology company and creator of the FDA-cleared LibAirty™ Airway Clearance System, today announced that RELACS (Real Life Evaluation of the LibAirty™ Airway ...
CHICAGO -- Brensocatib (Brinsupri) appeared to have a disease-modifying effect on structural lung changes in non-cystic fibrosis bronchiectasis at its higher dose, a CT substudy of the ASPEN trial ...
In March 2025, The Lancet Respiratory Medicine published a phase 2 clinical study article on China's first DPP-1 inhibitor, HSK31858, led by Academician Nan-shan Zhong and Professor Wei-jie Guan from ...
Bronchiectasis is a heterogeneous condition and may be encountered as a stand-alone pulmonary disease by primary care clinicians and specialists in pulmonary medicine. Bronchiectasis sometimes ...
Non–cystic fibrosis bronchiectasis (NCFB) is a chronic inflammatory condition of the lungs associated with respiratory infections and daily cough and sputum. Non-cystic fibrosis bronchiectasis. Image ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results